Fluicell AB has in-licensed the Dynaflow® Resolve Secondary Ion Channel Screening Platform Technology From Cellectricon AB
STOCKHOLM, Nov. 3, 2017 /PRNewswire/ -- Fluicell AB is extremely pleased to announce the signing of a license agreement with Cellectricon AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights.
The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The Dynaflow platform is complementary to Fluicell's BioPen system for single-cell-based discovery using optical readouts such as fluorescence microscopy. Both are state-of-the art microfluidic-based technologies which appeal to discerning medical, biology and pharma professionals worldwide, that wish to get the most out of their experiments.
"We will be pleased to serve the patch clamp and ion channels screening community with this unique product. The addition of the Dynaflow Resolve system will, in conjunction with the BioPen product line, give us great opportunities to further develop, expand and grow Fluicell's leading microfluidic cell-based tools in the pharmaceutic industry market," said Victoire Viannay, CEO at Fluicell.
"Dynaflow Resolve is a ground-breaking technology for patch clamp-based compound characterization and secondary screening, offering significant increase in data quality and productivity in the drug discovery process. Throughout the years, we've seen widespread adoption of the technology from big pharma. To ensure a smooth transition experience for our valued clients, Cellectricon will in partnership with Fluicell provide customer support during a transfer period," said Mattias Karlsson CEO at Cellectricon.
About Cellectricon
Based in Sweden, Cellectricon is a leading provider of advanced cell-based screening services to accelerate drug discovery. Exploiting their Cellaxess® Elektra platform, their Discovery Services offering is ideal for compound profiling in excitable primary cells and native tissue. Cellectricon services help researchers identify phenotypic effects in highly relevant biological models early enough in a project's lifecycle to add real value to the decision of whether to pursue or eliminate a compound, which translates to considerable cost savings in the drug development business.
For further information, visit www.cellectricon.com or contact:
Mattias Karlsson
CEO, Cellectricon
Email: [email protected]
About Fluicell
Fluicell is a Swedish biotech company that brings inspiration and innovation to life-science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, biophysics and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces costs, resources, and minimizes the use of animals. use, and animals. Fluicell's main target sectors include universities, the pharmaceutical industry, and national health laboratories.
For further information, visit www.fluicell.com or contact:
Victoire Viannay
CEO, Fluicell
Email: [email protected]
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Save in the context of fraud, no liability is accepted for any errors, omissions or inaccuracies in any of the information or opinions in these statements.
This information was brought to you by Cision http://news.cision.com
SOURCE Fluicell
Share this article